Oral Anticoagulant Adequacy in Non-Valvular Atrial Fibrillation in Primary Care: A Cross-Sectional Study Using Real-World Data (Fantas-TIC Study)

<b>Background:</b> Oral anticoagulants (OAs) are the treatment to prevent stroke in atrial fibrillation (AF). Anticoagulant treatment choice in non-valvular atrial fibrillation (NVAF) must be individualized, taking current guidelines into account. Adequacy of anticoagulant therapy under...

Full description

Bibliographic Details
Main Authors: M. Rosa Dalmau Llorca, Carina Aguilar Martín, Noèlia Carrasco-Querol, Zojaina Hernández Rojas, Emma Forcadell Drago, Dolores Rodríguez Cumplido, Josep M. Pepió Vilaubí, Elisabet Castro Blanco, Alessandra Q. Gonçalves, José Fernández-Sáez
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:International Journal of Environmental Research and Public Health
Subjects:
Online Access:https://www.mdpi.com/1660-4601/18/5/2244
id doaj-980c74fa5eb44428b5870fe0535a7f6a
record_format Article
spelling doaj-980c74fa5eb44428b5870fe0535a7f6a2021-02-25T00:04:22ZengMDPI AGInternational Journal of Environmental Research and Public Health1661-78271660-46012021-02-01182244224410.3390/ijerph18052244Oral Anticoagulant Adequacy in Non-Valvular Atrial Fibrillation in Primary Care: A Cross-Sectional Study Using Real-World Data (Fantas-TIC Study)M. Rosa Dalmau Llorca0Carina Aguilar Martín1Noèlia Carrasco-Querol2Zojaina Hernández Rojas3Emma Forcadell Drago4Dolores Rodríguez Cumplido5Josep M. Pepió Vilaubí6Elisabet Castro Blanco7Alessandra Q. Gonçalves8José Fernández-Sáez9Equip d’Atenció Primària Terres de l’Ebre, Institut Català de la Salut, 43500 Tortosa, Tarragona, SpainGAVINA Research Group, 43500 Tortosa, SpainGAVINA Research Group, 43500 Tortosa, SpainEquip d’Atenció Primària Terres de l’Ebre, Institut Català de la Salut, 43500 Tortosa, Tarragona, SpainEquip d’Atenció Primària Terres de l’Ebre, Institut Català de la Salut, 43500 Tortosa, Tarragona, SpainGAVINA Research Group, 43500 Tortosa, SpainEquip d’Atenció Primària Terres de l’Ebre, Institut Català de la Salut, 43500 Tortosa, Tarragona, SpainGrupo GAVINA, Campus Terres de l’Ebre, Universitat Rovira i Virgili, 43500 Tortosa, Tarragona, SpainGAVINA Research Group, 43500 Tortosa, SpainGrupo GAVINA, Campus Terres de l’Ebre, Universitat Rovira i Virgili, 43500 Tortosa, Tarragona, Spain<b>Background:</b> Oral anticoagulants (OAs) are the treatment to prevent stroke in atrial fibrillation (AF). Anticoagulant treatment choice in non-valvular atrial fibrillation (NVAF) must be individualized, taking current guidelines into account. Adequacy of anticoagulant therapy under the current criteria for NVAF in real-world primary care is presented. <strong>Methods:</strong> Cross-sectional study, with real-world data from patients treated in primary care (PC). Data were obtained from the System for the Improvement of Research in Primary Care (SIDIAP) database, covering 60,978 NVAF-anticoagulated patients from 287 PC centers in 2018. <strong>Results</strong>: In total, 41,430 (68%) were treated with vitamin K antagonists (VKAs) and 19,548 (32%) NVAF with direct-acting oral anticoagulants (DOACs). Inadequate prescription was estimated to be 36.0% and 67.6%, respectively. Most DOAC inadequacy (77.3%) was due to it being prescribed as a first-line anticoagulant when there was no history of thromboembolic events or intracranial hemorrhage (ICH). A total of 22.1% had missing estimated glomerular filtration rate (eGFR) values. Common causes of inadequate VKA prescription were poor control of time in therapeutic range (TTR) (98.8%) and ICH (2.2%). <strong>Conclusions:</strong> Poor adequacy to current criteria was observed, being inadequacy higher in DOACs than in VKAs. TTR and GFR should be routinely calculated in electronic health records (EHR) to facilitate decision-making and patient safety.https://www.mdpi.com/1660-4601/18/5/2244atrial fibrillationdirect oral anticoagulantsrenal functiontime in therapeutic rangevitamin K antagonists
collection DOAJ
language English
format Article
sources DOAJ
author M. Rosa Dalmau Llorca
Carina Aguilar Martín
Noèlia Carrasco-Querol
Zojaina Hernández Rojas
Emma Forcadell Drago
Dolores Rodríguez Cumplido
Josep M. Pepió Vilaubí
Elisabet Castro Blanco
Alessandra Q. Gonçalves
José Fernández-Sáez
spellingShingle M. Rosa Dalmau Llorca
Carina Aguilar Martín
Noèlia Carrasco-Querol
Zojaina Hernández Rojas
Emma Forcadell Drago
Dolores Rodríguez Cumplido
Josep M. Pepió Vilaubí
Elisabet Castro Blanco
Alessandra Q. Gonçalves
José Fernández-Sáez
Oral Anticoagulant Adequacy in Non-Valvular Atrial Fibrillation in Primary Care: A Cross-Sectional Study Using Real-World Data (Fantas-TIC Study)
International Journal of Environmental Research and Public Health
atrial fibrillation
direct oral anticoagulants
renal function
time in therapeutic range
vitamin K antagonists
author_facet M. Rosa Dalmau Llorca
Carina Aguilar Martín
Noèlia Carrasco-Querol
Zojaina Hernández Rojas
Emma Forcadell Drago
Dolores Rodríguez Cumplido
Josep M. Pepió Vilaubí
Elisabet Castro Blanco
Alessandra Q. Gonçalves
José Fernández-Sáez
author_sort M. Rosa Dalmau Llorca
title Oral Anticoagulant Adequacy in Non-Valvular Atrial Fibrillation in Primary Care: A Cross-Sectional Study Using Real-World Data (Fantas-TIC Study)
title_short Oral Anticoagulant Adequacy in Non-Valvular Atrial Fibrillation in Primary Care: A Cross-Sectional Study Using Real-World Data (Fantas-TIC Study)
title_full Oral Anticoagulant Adequacy in Non-Valvular Atrial Fibrillation in Primary Care: A Cross-Sectional Study Using Real-World Data (Fantas-TIC Study)
title_fullStr Oral Anticoagulant Adequacy in Non-Valvular Atrial Fibrillation in Primary Care: A Cross-Sectional Study Using Real-World Data (Fantas-TIC Study)
title_full_unstemmed Oral Anticoagulant Adequacy in Non-Valvular Atrial Fibrillation in Primary Care: A Cross-Sectional Study Using Real-World Data (Fantas-TIC Study)
title_sort oral anticoagulant adequacy in non-valvular atrial fibrillation in primary care: a cross-sectional study using real-world data (fantas-tic study)
publisher MDPI AG
series International Journal of Environmental Research and Public Health
issn 1661-7827
1660-4601
publishDate 2021-02-01
description <b>Background:</b> Oral anticoagulants (OAs) are the treatment to prevent stroke in atrial fibrillation (AF). Anticoagulant treatment choice in non-valvular atrial fibrillation (NVAF) must be individualized, taking current guidelines into account. Adequacy of anticoagulant therapy under the current criteria for NVAF in real-world primary care is presented. <strong>Methods:</strong> Cross-sectional study, with real-world data from patients treated in primary care (PC). Data were obtained from the System for the Improvement of Research in Primary Care (SIDIAP) database, covering 60,978 NVAF-anticoagulated patients from 287 PC centers in 2018. <strong>Results</strong>: In total, 41,430 (68%) were treated with vitamin K antagonists (VKAs) and 19,548 (32%) NVAF with direct-acting oral anticoagulants (DOACs). Inadequate prescription was estimated to be 36.0% and 67.6%, respectively. Most DOAC inadequacy (77.3%) was due to it being prescribed as a first-line anticoagulant when there was no history of thromboembolic events or intracranial hemorrhage (ICH). A total of 22.1% had missing estimated glomerular filtration rate (eGFR) values. Common causes of inadequate VKA prescription were poor control of time in therapeutic range (TTR) (98.8%) and ICH (2.2%). <strong>Conclusions:</strong> Poor adequacy to current criteria was observed, being inadequacy higher in DOACs than in VKAs. TTR and GFR should be routinely calculated in electronic health records (EHR) to facilitate decision-making and patient safety.
topic atrial fibrillation
direct oral anticoagulants
renal function
time in therapeutic range
vitamin K antagonists
url https://www.mdpi.com/1660-4601/18/5/2244
work_keys_str_mv AT mrosadalmaullorca oralanticoagulantadequacyinnonvalvularatrialfibrillationinprimarycareacrosssectionalstudyusingrealworlddatafantasticstudy
AT carinaaguilarmartin oralanticoagulantadequacyinnonvalvularatrialfibrillationinprimarycareacrosssectionalstudyusingrealworlddatafantasticstudy
AT noeliacarrascoquerol oralanticoagulantadequacyinnonvalvularatrialfibrillationinprimarycareacrosssectionalstudyusingrealworlddatafantasticstudy
AT zojainahernandezrojas oralanticoagulantadequacyinnonvalvularatrialfibrillationinprimarycareacrosssectionalstudyusingrealworlddatafantasticstudy
AT emmaforcadelldrago oralanticoagulantadequacyinnonvalvularatrialfibrillationinprimarycareacrosssectionalstudyusingrealworlddatafantasticstudy
AT doloresrodriguezcumplido oralanticoagulantadequacyinnonvalvularatrialfibrillationinprimarycareacrosssectionalstudyusingrealworlddatafantasticstudy
AT josepmpepiovilaubi oralanticoagulantadequacyinnonvalvularatrialfibrillationinprimarycareacrosssectionalstudyusingrealworlddatafantasticstudy
AT elisabetcastroblanco oralanticoagulantadequacyinnonvalvularatrialfibrillationinprimarycareacrosssectionalstudyusingrealworlddatafantasticstudy
AT alessandraqgoncalves oralanticoagulantadequacyinnonvalvularatrialfibrillationinprimarycareacrosssectionalstudyusingrealworlddatafantasticstudy
AT josefernandezsaez oralanticoagulantadequacyinnonvalvularatrialfibrillationinprimarycareacrosssectionalstudyusingrealworlddatafantasticstudy
_version_ 1724252316770500608